Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.
Tillett W, Allen A, Tucker L, Chandler D, Ciurtin C, Davis C, Dick A, Foulkes A, Gullick N, Helliwell P, Jadon D, Jones G, Kyle S, Madhok V, McHugh N, Parkinson A, Raine T, Siebert S, Smith C, Coates LC. Tillett W, et al. Among authors: gullick n. Rheumatology (Oxford). 2021 Apr 6;60(4):1588-1592. doi: 10.1093/rheumatology/keaa526. Rheumatology (Oxford). 2021. PMID: 33097948
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.
Tucker L, Allen A, Chandler D, Ciurtin C, Dick A, Foulkes A, Gullick N, Helliwell P, Jadon D, Jones G, Kyle S, Madhok V, McHugh N, Parkinson A, Raine T, Siebert S, Smith C, Tillett W, Coates LC. Tucker L, et al. Among authors: gullick n. Rheumatology (Oxford). 2022 Aug 30;61(9):3514-3520. doi: 10.1093/rheumatology/keac260. Rheumatology (Oxford). 2022. PMID: 35640653 No abstract available.
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.
Tucker L, Allen A, Chandler D, Ciurtin C, Dick A, Foulkes A, Gullick N, Helliwell P, Jadon D, Jones G, Kyle S, Madhok V, McHugh N, Parkinson A, Raine T, Siebert S, Smith C, Tillett W, Coates LC. Tucker L, et al. Among authors: gullick n. Rheumatology (Oxford). 2022 Aug 30;61(9):e255-e266. doi: 10.1093/rheumatology/keac295. Rheumatology (Oxford). 2022. PMID: 35640657 No abstract available.
Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC.
Coates LC, Garrood T, Gullick N, Helliwell P, Kent T, Marks J, Tillett W, Kaur-Papadakis D, Tahir H, van Haaren S, McInnes I. Coates LC, et al. Among authors: gullick n. Rheumatology (Oxford). 2022 Dec 23;62(1):e1-e3. doi: 10.1093/rheumatology/keac388. Rheumatology (Oxford). 2022. PMID: 35799375 Free article. No abstract available.
Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritis-study protocol for the MONITOR-PsA study, a trials within cohorts study design.
Rombach I, Tillett W, Jadon D, Tucker L, Watson M, Francis A, Sinomati Y, Eldridge L, Dritsaki M, Dutton SJ, Al-Mossawi H, Gullick N, Thompson B, Coates LC. Rombach I, et al. Among authors: gullick n. Trials. 2021 Mar 4;22(1):185. doi: 10.1186/s13063-021-05142-7. Trials. 2021. PMID: 33663566 Free PMC article.
Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England.
Quick V, Abusalameh M, Ahmed S, Alkoky H, Bukhari M, Carter S, Coath FL, Davidson B, Doddamani P, Dubey S, Ducker G, Griffiths B, Gullick N, Heaney J, Holloway A, Htut EEP, Hughes M, Irvine H, Kinder A, Kurshid A, Lim J, Ludwig DR, Malik M, Mercer L, Mulhearn B, Nair JR, Patel R, Robson J, Saha P, Tansley S; TOC STOP 2022 Investigators; Mackie SL. Quick V, et al. Among authors: gullick n. Rheumatology (Oxford). 2023 Nov 11:kead604. doi: 10.1093/rheumatology/kead604. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37952183
48 results